Future of In Vitro Diagnostics (IVD)
Noninvasive prenatal testing (NIPT), Liquid biopsy, Next-generation sequencing (NGS), and circulating tumor cell (CTC) tests etc. are considered as the future of the In Vitro Diagnostics (IVD). These areas of the IVD market is expected to witness a rapid growth in coming few years. In coming five years, the cost of NGS test will rise from $250 million to $800 million with the total number of NGS sales only rise from 100 million to 300 million. Though globally, the growth of IVD market is stagnant, it is predicted that NIPT will grow at a rate of 20% in USA and even more in abroad. Other future IVD devices include point of care biochemistry analyser (eg. Abbott i-STAT) blood gas analyser (eg. biosurfit spinit), immunology, haematology, and clinical chemistry analyser (eg. Acon Blood Glucose, Total Cholesterol, Cholesterol 3-1, Haemoglobin Meters and Hemoccult), and FOB test.